Heart procedure showdown: which ablation system sends fewer clots to the brain?

NCT ID NCT07610018

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will compare five different pulsed field ablation systems used to treat atrial fibrillation (an irregular heartbeat). The goal is to see which system causes the fewest tiny clots (microemboli) that travel to the brain during the procedure. One hundred adults with atrial fibrillation will be randomly assigned to one of the systems, and a special ultrasound will measure brain clots before and after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pulsed field ablation systems (PulseSelect, Varipulse, Farapulse, Sphere-9, Sphere-360)
What this could lead to
If one system causes fewer microemboli, it may become the preferred choice for safer atrial fibrillation ablation.
What could go wrong
This is an early-stage, small study (100 participants) that only measures a surrogate marker (microemboli), not actual stroke risk. Results may not change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABLATION OF ARRHYTHMIA'S are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UH Dubrava

    Zagreb, 10000, Croatia

  • University Hospital Center Sisters of Charity, Zagreb, Croatia

    Zagreb, 10000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.